These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29615123)

  • 1. Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study.
    Reed C; Belger M; Dell'Agnello G; Kahle-Wrobleski K; Sethuraman G; Hake A; Raskin J; Henley D
    Alzheimers Res Ther; 2018 Apr; 10(1):36. PubMed ID: 29615123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
    Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M
    J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
    Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
    J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
    Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
    Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
    Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
    J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
    Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
    N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study.
    Chandler JM; Ye W; Mi X; Doty EG; Johnston JA
    J Alzheimers Dis; 2024; 100(2):563-578. PubMed ID: 38875031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
    Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
    Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease progression by geographical region in a clinical trial setting.
    Henley DB; Dowsett SA; Chen YF; Liu-Seifert H; Grill JD; Doody RS; Aisen P; Raman R; Miller DS; Hake AM; Cummings J
    Alzheimers Res Ther; 2015; 7(1):43. PubMed ID: 26120369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer's disease.
    Lebrec J; Ascher-Svanum H; Chen YF; Reed C; Kahle-Wrobleski K; Hake AM; Raskin J; Naderali E; Schuster D; Heine RJ; Kendall DM
    BMC Geriatr; 2016 May; 16():93. PubMed ID: 27142529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive and Functional Decline in Patients With Mild Alzheimer Dementia With or Without Comorbid Diabetes.
    Ascher-Svanum H; Chen YF; Hake A; Kahle-Wrobleski K; Schuster D; Kendall D; Heine RJ
    Clin Ther; 2015 Jun; 37(6):1195-205. PubMed ID: 25676448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
    Liu-Seifert H; Siemers E; Price K; Han B; Selzler KJ; Henley D; Sundell K; Aisen P; Cummings J; Raskin J; Mohs R;
    J Alzheimers Dis; 2015; 47(1):205-14. PubMed ID: 26402769
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.